Latest news with #Illumina
Yahoo
2 days ago
- Business
- Yahoo
UAE Prenatal Testing Market to Triple by 2033: Driven by Tech Advancements and Maternal Health Awareness
Key drivers include increasing maternal age, healthcare advancements, and government support for early fetal screening. The market benefits from the rise in medical tourism and global diagnostic partnerships, despite challenges like cultural sensitivities and a lack of genetic counseling. Major players such as Eurofins, Roche, and Illumina enhance the UAE's prenatal care through innovative technologies and strategic partnerships. UAE Non-Invasive Prenatal Testing Market Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "UAE Non-Invasive Prenatal Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to UAE Non-Invasive Prenatal Testing Market is expected to reach US$ 64.46 million by 2033 from US$ 21.04 million in 2024, with a CAGR of 13.25% from 2025 to 2033. The UAE's non-invasive prenatal testing market is growing due to a number of factors, including growing maternal age, better access to healthcare, increasing awareness, government assistance, the need for early fetal screening, and a rise in incidences of genetic disorders. UAE Non-Invasive Prenatal Testing Industry OverviewDue to improvements in genetic screening technology and growing awareness among pregnant parents, the non-invasive prenatal testing (NIPT) market in the United Arab Emirates (UAE) is expanding steadily. NIPT uses a straightforward blood test from the mother to safely and effectively identify chromosomal abnormalities in the fetus. Because of its accuracy, early detection potential, and low danger in comparison to more conventional invasive techniques like amniocentesis, it has becoming more and more popular in the United Arab Emirates. Both public and commercial healthcare organizations are implementing NIPT as a common prenatal screening procedure as healthcare standards rise and prenatal care becomes more maternal age is a major risk factor for chromosomal abnormalities like Down syndrome, which raises the need for accurate prenatal screening and is one of the main causes driving this industry's rise. Furthermore, expanding insurance coverage, the presence of foreign healthcare practitioners, and the UAE government's initiatives to improve genetic health services all help to increase NIPT's accessibility and acceptability. The market is also supported by the nation's growing medical tourism industry, which draws patients from nearby areas looking for cutting-edge prenatal diagnostics, especially in locations like Dubai and Abu its promise, the UAE NIPT industry is beset by issues including low awareness among specific demographic groups and the exorbitant expense of testing for those without insurance. These obstacles are being addressed, meanwhile, by continued public education campaigns, the incorporation of genetics into national healthcare plans, and partnerships with international diagnostics firms. With advancements in bioinformatics and non-invasive technologies anticipated to further improve the precision and reach of prenatal screening services, the NIPT sector in the United Arab Emirates is well-positioned for sustained development as precision medicine continues to Drivers for the UAE Non-Invasive Prenatal Testing Market Supportive Government PoliciesThe UAE's non-invasive prenatal testing (NIPT) sector is expanding thanks in large part to supportive government legislation. As part of its larger national healthcare policy, the government has made maternal and fetal health a top priority, investing heavily in early diagnostic technologies and updating hospital infrastructure. The National Genome Strategy and the UAE's Vision 2031 initiatives center on incorporating cutting-edge genetic technology into standard medical treatment. While regulatory agencies make ensuring that these technologies are used in a safe and moral manner, public health campaigns also seek to increase awareness about prenatal screening. These initiatives, together with advantageous laws and alliances with international biotech companies, are creating a healthcare climate that encourages innovation and the broad use of NIPT throughout the Tourism GrowthThe non-invasive prenatal testing (NIPT) industry in the United Arab Emirates is growing due in large part to the rise of medical tourism, particularly in locations like Dubai and Abu Dhabi. The nation has established itself as a regional center for top-notch, specialized medical treatment, drawing clients from Asia, Africa, and the Middle East. The UAE's highly developed healthcare system, internationally recognized facilities, and access to state-of-the-art diagnostic tools like NIPT attract patients from outside. For pregnant moms looking for early and precise fetal screening, prenatal care facilities that offer individualized attention and minimal wait periods are particularly alluring. The UAE's standing as a destination for cutting-edge prenatal diagnostics is further reinforced by government funding for healthcare tourism and continuous initiatives to enhance service of Global Diagnostic CompaniesOne of the main factors propelling the non-invasive prenatal testing (NIPT) industry's expansion in the United Arab Emirates is the arrival of international diagnostic and genomics firms. To increase access to cutting-edge prenatal screening technology, foreign companies are establishing strategic alliances with regional healthcare providers, labs, and governmental organizations. The accuracy, speed, and scope of NIPT services are improved by these partnerships' introduction of cutting-edge technologies including high-throughput sequencing and AI-powered data processing. Furthermore, foreign actors raise the general level of prenatal care in the United Arab Emirates by assisting with knowledge transfer, workforce training, and adherence to international quality standards. The country's larger objectives of becoming a regional leader in precision healthcare and genomic medicine are supported by this infusion of knowledge and in the UAE Non-Invasive Prenatal Testing Market Cultural and Religious SensitivitiesThe UAE's adoption of non-invasive prenatal testing (NIPT) is significantly hampered by cultural and religious sensitivities. The ethical ramifications of prenatal testing, especially with regard to possible judgments about pregnancy termination, might restrict acceptability in an area where traditional values and religious views are crucial in family and healthcare decisions. Because of religious beliefs about the sanctity of life, worries about disrupting natural processes, or fears of social disapproval, some families might be reluctant to undergo genetic testing. Even when NIPT is advised by a doctor, these issues may cause reluctance to choose it. Building understanding and confidence in prenatal screening necessitates ethical counseling, culturally relevant public education, and collaboration with community and religious of Genetic Counseling ServicesOne major obstacle to the efficient use of non-invasive prenatal testing (NIPT) in the United Arab Emirates is the lack of qualified genetic counselors. Even though NIPT's technology is sophisticated and becoming more widely available, many patients may not have the assistance they need to understand complicated genetic data. Expectant parents may misinterpret test findings without the right counseling, which might cause needless worry or poor choices. In a culturally diverse nation like the United Arab Emirates, where language proficiency and cultural awareness are crucial for successful communication, this disparity is especially significant. Existing healthcare providers are likewise strained by the shortage of skilled workers. To remedy this deficiency, it is imperative to integrate remote or tele-counseling services, expand training programs, and provide incentives for genetic counseling expertise. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $21 Million Forecasted Market Value (USD) by 2033 $64.5 Million Compound Annual Growth Rate 13.2% Regions Covered United Arab Emirates Report Scope: UAE Non-Invasive Prenatal Testing Market Segment Component Instruments Kits and Reagents Services Application Down Syndrome (Trisomy 21) Edwards Syndrome (Trisomy 18) Patau Syndrome (Trisomy 13) Turner Syndrome Other Applications End User Hospitals Diagnostic Labs The key players have been analyzed by: Overview Key Persons Recent Development & Strategies Financial Insights Key Players Analyzed: Eurofins Scientific F. Hoffmann-La Roche Ltd Invitae Corporation Illumina Inc. Natera Inc. Centogene NV Qiagen For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment UAE Non-Invasive Prenatal Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
Illumina Inc. ILMN recently introduced PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. PromoterAI turns data into insights to help researchers accelerate new breakthroughs in diagnosis for rare diseases. It is the latest addition to the company's artificial intelligence ("AI") and software portfolio. Since the announcement on May 29, ILMN's shares declined 0.2%, closing at $84.28 yesterday. The company is breaking new ground with AI technology. In 2019, the Illumina Artificial Intelligence Lab released SpliceAI, a deep learning tool for interpreting noncoding cryptic splice mutations. In 2023, Illumina released PrimateAI-3D, which predicts the pathogenicity of protein-coding variants based on evolutionary conservation and protein structure. PromoterAI is the latest genomic AI algorithmic innovation from Illumina. As a result, we expect the news to boost market sentiment toward ILMN stock. Illumina presently has a market capitalization of $13.34 billion. The company's earnings yield of 5.1% sits comfortably against the industry's -31.7%. It delivered a trailing four-quarter average earnings surprise of 56.4%. Built on state-of-the-art deep learning neural networks, PromoterAI brings unprecedented precision to the interpretation of promoter variants. With PromoterAI applied to whole-genome sequencing ("WGS") data analysis, clinical researchers are empowered to better understand the etiology and drug target potential for rare genetic diseases, common diseases and oncology. PromoterAI will be accessible through Illumina Connected Software, and it is now available as part of DRAGEN secondary analysis. Precomputed PromoterAI scores for all human promoter single-nucleotide variants are freely available for academic and noncommercial research use. Currently, only about 30% of rare disease patients receive an accurate diagnosis from exome sequencing. For many patients, insights may be hidden in what are known as "noncoding regions," which comprise over 98% of the genome and may hold the key to increasing the diagnostic rate. Promoters are key noncoding elements that define where transcription of a gene begins. When promoters are disrupted by genetic mutations, it can have profound consequences for downstream gene expression. The PromoterAI algorithm interprets the genetic sequence of promoters, thus opening the door to precise diagnoses for more patients with rare diseases. Image Source: Zacks Investment Research Per Dimension Market Research's report, AI in the genomics market is estimated to be valued at $1.40 billion in 2025. It is further anticipated to reach $44.93 billion by 2034 at a compound annual growth rate of 47%. Key factors driving the market growth are increasing demand for precision medicine, rising R&D expenditure and growing demand for effective handling tools for managing large data. On Tuesday, Illumina received approval from Japan's Ministry of Health, Labour and Welfare for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device). The TSO Comprehensive is the first U.S. FDA-approved, distributable comprehensive genomic profiling in vitro diagnostics (IVD) kit with pan-cancer CDx claims in the United States. Over the past three months, ILMN's shares have risen 0.1% against the industry's 8.5% decline. Illumina currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space include Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health carry a Zacks Rank #2 (Buy) each. You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry's 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5%. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health's shares have surged 172.5% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates in two of the trailing four quarters, matched in one and missed in the other, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Prestige Consumer Healthcare's fiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry's 10.1% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
5 days ago
- Health
- Yahoo
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis
Illumina, Inc. (NASDAQ:ILMN) has introduced PromoterAI, a breakthrough AI tool designed to detect disease-causing mutations in the noncoding promoter regions of the genome, areas often overlooked in clinical diagnostics. Featured in Science, the study shows PromoterAI could explain up to 6% of undiagnosed rare disease cases, potentially doubling diagnostic success when paired with existing AI tools. A research facility with medical professionals surrounded by diagnostic equipment. While most current diagnostics focus on protein-coding regions, PromoterAI analyzes promoter sequences, key regulators of gene activity, using deep learning. 'This opens new possibilities for patients who previously had no genetic answers,' said Dr. Kyle Farh, head of Illumina, Inc. (NASDAQ:ILMN)'s AI Lab. The tool joins Illumina, Inc. (NASDAQ:ILMN)'s AI portfolio, including SpliceAI and PrimateAI-3D, and integrates with its DRAGEN analysis system. It is freely available for academic research through Illumina Connected Software, offering precomputed scores to prioritize harmful mutations quickly. While we acknowledge the potential of ILMN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ILMN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
5 days ago
- Health
- Yahoo
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis
Illumina, Inc. (NASDAQ:ILMN) has introduced PromoterAI, a breakthrough AI tool designed to detect disease-causing mutations in the noncoding promoter regions of the genome, areas often overlooked in clinical diagnostics. Featured in Science, the study shows PromoterAI could explain up to 6% of undiagnosed rare disease cases, potentially doubling diagnostic success when paired with existing AI tools. A research facility with medical professionals surrounded by diagnostic equipment. While most current diagnostics focus on protein-coding regions, PromoterAI analyzes promoter sequences, key regulators of gene activity, using deep learning. 'This opens new possibilities for patients who previously had no genetic answers,' said Dr. Kyle Farh, head of Illumina, Inc. (NASDAQ:ILMN)'s AI Lab. The tool joins Illumina, Inc. (NASDAQ:ILMN)'s AI portfolio, including SpliceAI and PrimateAI-3D, and integrates with its DRAGEN analysis system. It is freely available for academic research through Illumina Connected Software, offering precomputed scores to prioritize harmful mutations quickly. While we acknowledge the potential of ILMN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ILMN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Health
- Yahoo
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases. By turning data into insights, this technology is expected to help researchers accelerate new breakthroughs in diagnosis for rare diseases. Currently, only about 30% of rare disease patients receive an accurate diagnosis from exome sequencing. For many patients, insights may be hidden in what are known as "noncoding regions," which comprise over 98% of the genome and may hold the key to increasing the diagnostic rate. Promoters are key noncoding elements that define where transcription of a gene begins. When promoters are disrupted by genetic mutations, it can have profound consequences for downstream gene expression. The PromoterAI algorithm interprets the genetic sequence of promoters, thus opening the door to precise diagnoses for more patients with rare diseases. "Illumina is breaking new ground with this AI technology," said Kyle Farh, MD, PhD, vice president, distinguished scientist, and head of the Illumina Artificial Intelligence Lab. "Combined with whole-genome sequencing, we believe PromoterAI holds the power to improve the rate of rare disease diagnosis by identifying previously overlooked variants in the noncoding genome. One of the challenges of searching for the genetic causes of rare disease is that, even if the protein-coding sequence of a gene is free from variants, mutations in that gene's promoter region can prevent it from being properly expressed." Built on state-of-the-art deep learning neural networks, PromoterAI brings unprecedented precision to the interpretation of promoter variants. With PromoterAI applied to whole-genome sequencing (WGS) data analysis, clinical researchers are empowered to better understand the etiology and drug target potential for rare genetic diseases, common diseases, and oncology. PromoterAI is the latest genomic AI algorithmic innovation from Illumina. In 2019, the Illumina Artificial Intelligence Lab released SpliceAI, a deep learning tool for interpreting noncoding cryptic splice mutations. In 2023, Illumina released PrimateAI-3D, which predicts the pathogenicity of protein-coding variants based on evolutionary conservation and protein structure. The study demonstrates that when used together, Illumina's AI classification prediction tools—PromoterAI, PrimateAI-3D, and SpliceAI—effectively double the diagnostic yield compared to using protein-truncating variants alone. "PromoterAI is the latest addition to our AI and software portfolio, which has delivered leading quality, prediction accuracy, and comprehensiveness to turn data into valuable insights for our customers," said Rami Mehio, vice president, and global head of Software and Informatics. PromoterAI will be accessible through Illumina Connected Software and it is available today as part of DRAGEN™ secondary analysis. Precomputed PromoterAI scores for all human promoter single-nucleotide variants are freely available for academic and noncommercial research use. Illumina Connected Software supports seamless integration with next-generation sequencing and array workflows for genomics and multiomics. Researchers, bioinformaticians, and clinical geneticists can use Illumina Connected Software to prioritize variants that are important to a case, gain critical insights, and accelerate their precision medicine dry lab operations. Use of forward-looking statements This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) customer uptake of, and satisfaction with, new products and services; and (iii) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. ContactsInvestors:Brian BlanchettIR@ Media:Christine DouglassPR@ View original content to download multimedia: SOURCE Illumina, Inc.
